AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01692769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
Study NCT01692769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
Study NCT02386332 — intervention group
Intervention type: PROCEDURE
Intervention: transplantation
Study NCT01052974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropivacaine
Description: A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo.
Study NCT01052974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo.
Study NCT00914641 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban IR
Description: immediate release tablet, 10 mg, single dose
Study NCT00914641 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban MR1
Description: modified release tablet 1, 10 mg, single dose
Study NCT00914641 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban MR2
Description: modified release tablet 2, 10 mg, single dose
Study NCT00914641 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban MR3
Description: modified release tablet 3, 10 mg, single dose
Study NCT01687920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (1.25mg)
Study NCT01687920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (2.5mg)
Study NCT01687920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (5mg)
Study NCT01687920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (7.5mg)
Study NCT01687920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (10mg)
Study NCT01138462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intervention
Description: 5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation.
Study NCT03333512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
Study NCT02411669 — intervention group
Intervention type: OTHER
Intervention: Operational patient centered care tools
Description: The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done.
Study NCT04638036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures
Study NCT04638036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescent molecular endoscopy and surgery
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe can be inserted through the standard working channel of the standard clinical endoscope for fluorescent endoscopy. Fluorescence imaging will be performed post the chemoradiotherapy.
Study NCT04545931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation
Description: 34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
Study NCT04545931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Acetate
Description: 0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
Study NCT01888991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Preload and Exercise Intervention
Description: A glucose preload and exercise were administered to examine the modulate substrate oxidation
Study NCT01243203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Champix
Description: Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
Study NCT01751243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allo-depleted lymphocyte infusion
Description: Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
Study NCT01751243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Haploidentical transplantation of hematopoietic progenitors
Description: Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
Study NCT03206606 — intervention group
Intervention type: DEVICE
Intervention: SPIRO
Description: Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
Study NCT03416517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 or 8 mg/d po D1-14 q3w
Study NCT03416517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
Study NCT03157999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (CAST)
Description: Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~* care coordination and system navigation (including facilitating timely primary care follow-up);~* medication management;~* assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~* evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~* patient and caregiver education; and goal setting and problem-solving therapy.
Study NCT02308904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw/Semen Exam
Description: Females:~1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~1. Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~2. Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older).
Study NCT02308904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective data/Chart Review/Relevant Clinical Results
Description: 1. 1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2\* MRI. 4. Ferritin levels.~2. NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~3. 1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~4. 1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~5. Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement.
Study NCT02308904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pituitary MRI
Description: MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted.
Study NCT01132768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
Study NCT01132768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
Study NCT03795545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy
Study NCT00992485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADIPOPLUS
Description: autologous adipose-derived stem cell
Study NCT05255133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid biopsies
Description: Blood sampling will be done at regular intervals
Study NCT05255133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
Description: Scans will be done at regular intervals
Study NCT06607393 — intervention group
Intervention type: DRUG
Intervention: Pembrolizumab
Study NCT06607393 — intervention group
Intervention type: DRUG
Intervention: Pemetrexed
Study NCT06607393 — intervention group
Intervention type: DRUG
Intervention: Cisplatin
Study NCT06607393 — intervention group
Intervention type: DRUG
Intervention: Carboplatin
Study NCT03591003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Yellow fever neutralizing antibodies measure
Description: Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
Study NCT01817998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
Study NCT01817998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
Study NCT03433768 — intervention group
Intervention type: GENETIC
Intervention: Real time PCR
Description: We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
Study NCT00113217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV on day 1 of each 14-day cycle.
Study NCT02110550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPS.emmax endocrown
Study NCT03640715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ENVU
Description: ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.
Study NCT02098915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous metoclopramide
Description: the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
Study NCT02098915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
Study NCT01228695 — intervention group
Intervention type: OTHER
Intervention: sleep study
Description: The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
Study NCT02621008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Reduction& Healthy living
Description: Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
Study NCT01620437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
Study NCT03432585 — intervention group
Intervention type: BEHAVIORAL
Intervention: Applicant Survey
Description: This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
Study NCT01913652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study NCT01792024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visualase Thermal Therapy
Description: MR guided laser ablation of prostate cancer
Study NCT01792024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MR-guided LITT
Study NCT01959269 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY 73-4506)
Description: As determined by the treating physician
Study NCT04377399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks
Study NCT03833336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
Study NCT03833336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
Study NCT03833336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferroglycine Sulfate
Description: One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
Study NCT03833336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrosomial Iron
Description: One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
Study NCT03385629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CSM theory-based didactic education and skills training
Description: Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
Study NCT03385629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AAP-based didactic education
Description: American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
Study NCT03385629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice EMR changes
Description: Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
Study NCT04825106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic context
Description: A life-threatening situation occurs in 3 different contexts
Study NCT05012514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT RED
Description: Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap. A cluster applicator was used using the parameters described in table 1.~For therapy, the equipment Antares® was used, IBRAMED- Indústria Brasileira de Equipamentos Eletromédicos EIRELI \[EIRELI Brazilian Industry of Electromedical Equipment\], approved by Anvisa Nº 10360310037. Figure 1.
Study NCT04711395 — intervention group
Intervention type: DEVICE
Intervention: measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.
Description: subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
Study NCT00192465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp.1: 3 mg/kg IV (single dose)
Study NCT00192465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp. 2: 15 mg/kg IV (single dose)
Study NCT00192465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp. 3: 30 mg/kg IV (single dose)
Study NCT00192465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp. 4: 3 mg/kg IM (single dose)
Study NCT00192465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp.5: 3 mg/kg IM (two doses)
Study NCT02543801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Periarticular injection
Study NCT02543801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Periarticular injection
Study NCT02543801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Included as an element of the Liposomal bupivacaine intervention periarticular injection
Study NCT02543801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Included as an element of both interventions as a standard of care periarticular injection
Study NCT02543801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Included as an element of both interventions as a standard of care periarticular injection
Study NCT00724126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Study NCT00724126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01436175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Description: SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
Study NCT02543801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Included as an element of both interventions as a standard of care periarticular injection
Study NCT01921959 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intervention
Description: Postpartum women are randomized to intervention or control group
Study NCT04631757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab + SOX + Radiotherapy
Description: Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d